Back to Directory

Emily Brown

Email

embrown@fhi360.org

Phone

919-321-3806

Institution

FHI 360

Title

Clinical Research Manager

Address

FHI 360
359 Blackwell Street
Suite 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children

DAIDS Number

38505

Research Area

Tuberculosis

Study Status

In Development

IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1

DAIDS Number

38962

Research Area

Therapeutics

Study Status

In Development

IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP)

DAIDS Number

38846

Research Area

Tuberculosis

Study Status

Pending

P1101: Phase I/II Dose-Finding, Safety, Tolerance and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-infected and TB Co-infected Infants and Children

DAIDS Number

11831

Research Area

Treatment

Study Status

Concluded

IMPAACT 2009 : Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants

DAIDS Number

30020

Research Area

Therapeutics

Study Status

Closed to Follow Up

Show All